Simulations Plus, Inc. Q2 2026 Earnings Recap

SLP Q2 2026 April 10, 2026

Get alerts when SLP reports next quarter

Simulations Plus delivered a strong second quarter with 8% revenue growth to $24.3 million, supported by robust software and service segment performance, and maintained solid margins and client renewal rates.

Earnings Per Share Beat

$0.35 vs $0.27 est.

+29.6% surprise

Revenue Beat

24291000 vs 21659140 est.

+12.2% surprise

Market Reaction

1-Day +0.38%

5-Day +12.7%

30-Day +23.63%

See SLP alongside your other holdings

Add to your portfolio — free

Key Takeaways

Total revenue rose 8%, driven by 9% software and 8% service segment growth, surpassing guidance.
Software revenue from ADMET Predictor grew 19%, reflecting ongoing strength in discovery applications.
Client base expanded to 297 with an average revenue per client of $124,000 and a renewal rate of 91% for the quarter.
The company is strategically leveraging AI, establishing collaborations with major pharmaceutical firms to embed AI into drug development workflows.
Despite near-term challenges in clinical operations revenue, the firm’s long-term positioning remains focused on durable scientific engines and AI-enhanced biosimulation solutions.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit SLP on AllInvestView.

Previous Q1 2026